Blog
RSS FeedPosted by Michael Wonder on 18 Jan 2023
HUTCHMED announces agreement with NHSA for inclusion of Orpathys in the National Reimbursement Drug List in China
18 January 2023 - HUTCHMED China today announces, following negotiations with the China National Healthcare Security Administration, Orpathys (savolitinib) has been ...
Posted by Michael Wonder on 18 Jan 2023
BeiGene announces expansion of coverage on China’s National Reimbursement Drug List
18 January 2023 - Four new indications added for tislelizumab and all nine approved indications now included in National Reimbursement Drug List. ...
Posted by Michael Wonder on 18 Jan 2023
Paratek Pharmaceuticals announces inclusion of Nuzyra (omadacycline) in China’s National Reimbursement Drug List (NRDL)
18 January 2023 - National Healthcare Security Administration adds Nuzyra to NRDL for treatment of community-acquired bacterial pneumonia and acute bacterial ...
Posted by Michael Wonder on 17 Jan 2023
China NMPA approves Bio-Thera Solutions’ BAT1806, a biosimilar to Actemra (tocilizumab)
16 January 2023 - World’s first approved biosimilar to Actemra. ...
Posted by Michael Wonder on 16 Jan 2023
China NMPA approved penpulimab for first-line treatment of locally advanced or metastatic quamous NSCLC
15 January 2023 - Akeso announced that the anti PD-1 monoclonal antibody drug penpulimab, co-developed by the Company with Sino ...
Posted by Michael Wonder on 13 Jan 2023
Takeda’s Exkivity (mobocertinib) receives approval from the NMPA of China, becoming the first and only therapy available for patients with EGFR exon20 insertion positive NSCLC
12 January 2023 - Exkivity is the first category-1 innovative drug approved for Takeda China following a Phase 2 global pivotal ...
Posted by Michael Wonder on 13 Jan 2023
COVID treatment molnupiravir to hit Chinese market on Friday
12 January 2023 - The COVID-19 treatment molnupiravir is expected to hit the Chinese market on Friday, after passing its ...
Posted by Michael Wonder on 12 Jan 2023
Pfizer's Paxlovid not included in China's national insurance
9 January 2023 - China will not include Pfizer’s COVID-19 treatment drug in a national reimbursement list that would have allowed ...
Posted by Michael Wonder on 03 Jan 2023
Legend Biotech announces acceptance of its new drug application for ciltacabtagene autoleucel in China
2 January 2023 - Legend Biotech announced today that China’s NMPA has formally accepted its new drug application for ciltacabtagene ...
Posted by Michael Wonder on 02 Jan 2023
BeiGene announces acceptance of twelfth regulatory submission in China for PD-1 inhibitor tislelizumab
30 December 2022 - Submission seeks marketing authorisation for first-line treatment of unresectable or metastatic hepatocellular carcinoma. ...
Posted by Michael Wonder on 02 Jan 2023
China CDE/NMPA recommends priority review for Nefecon for the treatment of primary IgA nephropathy
30 December 2022 - Calliditas Therapeutics' partner Everest Medicines today announced that the Center for Drug Evaluation of the China ...
Posted by Michael Wonder on 26 Dec 2022
BioArctic's partner Eisai initiates BLA submission of data for lecanemab in China
22 December 2022 - BioArctic's partner Eisai announced today that they have initiated submission of data for biologics license application ...
Posted by Michael Wonder on 28 Nov 2022
Ferinject approved in China for the treatment of iron deficiency in adult patients
28 November 2022 - China has the world’s largest iron deficiency anaemia population with estimated prevalence of 15%. ...
Posted by Michael Wonder on 28 Nov 2022
Lantheus announces the approval of Definity (perflutren lipid microsphere) by China’s NMPA
28 November 2022 - Definity is the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms. ...
Posted by Michael Wonder on 22 Nov 2022
Junshi Biosciences announces approval of supplemental application for additional indications of adalimumab injection
22 November 2022 - Shanghai Junshi Biosciences announced today that the supplemental application for additional indications of adalimumab injection (UBP1211) for ...